Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

32.74
-0.6700-2.01%
Post-market: 32.910.1700+0.52%19:48 EDT
Volume:1.71M
Turnover:56.48M
Market Cap:5.68B
PE:-15.16
High:33.93
Open:33.37
Low:32.69
Close:33.41
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:0.93
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:12.15
PE(LYR):-12.84

Loading ...

Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application

TIPRANKS
·
Yesterday

Cogent Biosciences, - FDA States no Advisory Committee Planned and no Review Issues Identified

THOMSON REUTERS
·
Yesterday

Cogent Biosciences Announces FDA Acceptance of New Drug Application (Nda) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (Advsm)

THOMSON REUTERS
·
Yesterday

Cogent Biosciences, - FDA Accepts Nda for Bezuclastinib in Advsm with Pdufa Date June 29, 2027

THOMSON REUTERS
·
Yesterday

Cogent Biosciences - to Purchase Minimum Percentages of Bezuclastinib Products from Hovione - SEC Filing

THOMSON REUTERS
·
Sep 03

Cogent Biosciences - Agreement Effective for Five-Year Term with Automatic Two-Year Renewals - SEC Filing

THOMSON REUTERS
·
Sep 03

Cogent Biosciences - Enters Commercial Supply Agreement with Hovione on Sept 1, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 03

Cogent Biosciences Signs Hovione Supply Deal for Bezuclastinib Tablets

Reuters
·
Sep 03

Cogent Biosciences Director Arlene Morris Disposes of USD 1.69 Million in Common Shares

Reuters
·
Sep 01

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

Simply Wall St.
·
Aug 17

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next

Simply Wall St.
·
Aug 16

Cogent Biosciences, Inc. : Leerink Partners Cuts Target Price to $60 from $72

THOMSON REUTERS
·
Aug 12

Wedbush Reaffirms Their Buy Rating on Cogent Biosciences (COGT)

TIPRANKS
·
Aug 11

Cogent Biosciences, Inc. : Guggenheim Raises Target Price to $52 from $45

THOMSON REUTERS
·
Aug 11

U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics

Reuters
·
Aug 11

Cogent Biosciences Files for USD 400 Million At-the-Market Stock Offering

Reuters
·
Aug 11

Cogent Biosciences - May Offer up to $400 Mln in Common Stock Through Guggenheim Securities - SEC Filing

THOMSON REUTERS
·
Aug 11

Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates

Reuters
·
Aug 11

Bionano Genomics Q2 Revenue Rises on Increased Clinical Adoption

Reuters
·
Aug 11

Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise

Reuters
·
Aug 11